Creative Biolabs Provides the Services of One-Stop CAR-therapy Development
Creative Biolabs is the distinguished entity showing its prominence in the field of chimeric antigen receptors and CAR-T immunotherapy with the world's largest collection of CAR products of distinct generations aiming at different biomakers, and it is on its way to renovate the next generation CAR technologies to make achievements of great significance. The company is now providing one-stop CAR-therapy development services, making efforts to assisting the bioscience research in tumor treatment.
Currently, Chimeric Antigen Receptors(CARs) technology has been drawn great attention to its success in hematological therapy in terms of cancer. Manager of Creative Biolabs adverted in an interview that this new therapy has been celebrated as a medical breakthrough together with checkpoint prohibition owing to the merits detected in clinical trials with patients of chemotherapy-refractory B62cell malignancies, and more importantly the research process would become more efficient with the services of one-stop CAR-therapy development which are adorably provided in Creative Biolabs.
As for CAR-T immunotherapy, Creative Biolabs provide people in need with the one-step CAR-therapy development service, and a wide range of unique services are available, including biomaker identification and selection which helps discover the potential cancer biomarkers by diverse gene and protein analysis technologies and the select the most suitable CAR-T therapy targets with better potency and lower toxicity. High affinity ScFv generation is also available in Creative Biolab, which entails in-house inescapable antibody sequence database with a collection of more than 6,000 antibody products, antibody discovery by mouse, rabbit, human library as well as hybridomas, and scFv affinity measurement and optimization. More services also include CAR Design and Construction, CAR-T preclinical in vivo assay, CAR-T Gene Packaging and Delivering, CAR cell in vitro assay service, as well as CAR clinical trials, and all of them are design to meet the need of CAR-T immunotherapy and promote the revolution of cancer treatment with it.
About Creative Biolabs:
Since our inception in 2004, our research and service capacity have expanded to the entire new drug discovery and development pipeline, including an early discovery, preclinical testing, process development, cGMP manufacturing, phase 1-III clinical trails. As a global company, we have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline.